Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Epidemiology
- Internal Medicine
- Psychiatry and Mental Health
- Hematology
- Pediatrics
- Endoscopy
- Oncology Cases
- Obstetrics and Gynecology
Abstract
Citation: Ann Clin Case Rep. 2017;2(1):1281.DOI: 10.25107/2474-1655.1281
Development of Amyotrophic Lateral Sclerosis during Ustekinumab use for Refractory Crohn′s Disease
Greenup AJ and Rosenfeld G
Department of Medicine-Gastroenterology, University of British Columbia, Canada
*Correspondance to: Greenup AJ
PDF Full Text Case Report | Open Access
Abstract:
Ustekinumab, an interleukin 12/23 monoclonal antibody, has recently been approved for use in Crohn’s Disease (CD). Safety data to date has been reassuring, however this is in the context of clinical trials and limited clinical experience in psoriasis, psoriatic arthritis and CD. We report the use of ustekinumab in a patient with CD who developed neurological symptoms concerning for amyotrophic lateral sclerosis soon after commencement. While no direct causative association can be drawn, this case emphasises the need for ongoing post-marketing surveillance with new therapies.
Keywords:
Cite the Article:
Greenup AJ, Rosenfeld G. Development of Amyotrophic Lateral Sclerosis during Ustekinumab use for Refractory Crohn′s Disease. Ann Clin Case Rep. 2017; 2: 1281.
